Loading...
•
Jun 30, 2020
Allakos Q2 2020 Earnings Report
Reported financial results for the second quarter and provided an update of its ongoing development activities.
Key Takeaways
Allakos reported a net loss of $39.3 million in the second quarter of 2020, compared to $19.1 million in the same period in 2019. The company ended the quarter with $454.9 million in cash, cash equivalents and marketable securities.
Patient enrollment was initiated in a Phase 3 study of AK002 in patients with eosinophilic gastritis (EG) and/or eosinophilic duodenitis (EoD).
Patient enrollment was initiated in a Phase 2/3 study of AK002 in patients with eosinophilic esophagitis (EoE).
The Phase 1 safety, tolerability and pharmacokinetics study of the subcutaneous formulation of AK002 is fully enrolled.
The non-interventional study examining the prevalence of EG, EoD, and mast cell gastrointestinal disease (MGID) in patients with chronic functional gastrointestinal disease is fully enrolled.
Allakos
Allakos
Forward Guidance
This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995.